🇺🇸 FDA
Patent

US 8415365

Compositions and methods for inhibition of the JAK pathway

granted A61KA61K31/343A61K31/436

Quick answer

US patent 8415365 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/343, A61K31/436, A61K31/505, A61K31/506